Arrowhead Reports Promising Interim Data for Obesity RNAi Trials

Arrowhead Pharmaceuticals ( (ARWR) ) has issued an update.

On January 6, 2026, Arrowhead Pharmaceuticals reported interim data from two ongoing Phase 1/2a trials of its investigational RNAi obesity candidates ARO-INHBE and ARO-ALK7, showing meaningful improvements in body composition and weight in obese participants, including those with type 2 diabetes. ARO-INHBE monotherapy produced dose-dependent reductions in serum Activin E and reduced visceral and liver fat while modestly increasing lean tissue, and in combination with tirzepatide in obese patients with type 2 diabetes, it roughly doubled weight loss (–9.4% vs. –4.8% at week 16) and tripled reductions in visceral, total, and liver fat versus tirzepatide alone. ARO-ALK7 emerged as the first RNAi drug to demonstrate adipocyte gene target silencing in humans, achieving up to 94% knockdown of ALK7 mRNA and a placebo-adjusted 14.1% visceral fat reduction after a single dose, suggesting the Activin E/ALK7 pathway could be harnessed to improve outcomes in obese patients, particularly those with diabetes who typically respond less well to incretin therapies. Both candidates were generally well tolerated, with mostly mild adverse events and no treatment-related serious safety signals to date, bolstering Arrowhead’s strategic push into obesity and broader cardiometabolic indications and reinforcing its positioning as a leading developer of RNAi-based therapies targeting both liver and adipose tissue.

The most recent analyst rating on (ARWR) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.

Spark’s Take on ARWR Stock

According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.

The score is driven by strong technical momentum and a positive earnings-call backdrop (FDA approval and meaningful partnership/milestone economics). Financial performance is improving but still volatile with slightly negative net income, while valuation is a headwind due to a highly negative P/E and no dividend yield.

To see Spark’s full report on ARWR stock, click here.

More about Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with a growing focus on cardiometabolic diseases including obesity and type 2 diabetes. Leveraging its proprietary Targeted RNAi Molecule (TRiM) platform, the company is developing agents that silence disease-related genes in tissues such as the liver and adipose tissue, aiming to create potentially best-in-class treatments that complement existing incretin-based therapies.

Average Trading Volume: 2,309,688

Technical Sentiment Signal: Buy

Current Market Cap: $8.68B

For detailed information about ARWR stock, go to TipRanks’ Stock Analysis page.